CJC-1295 vs Ipamorelin: What's the Difference?

If you are looking at growth-hormone research peptides, CJC-1295 and Ipamorelin come up constantly - often together. They are frequently described as similar, but they are different compounds that work through different mechanisms. Here is the plain-English difference.

The short answer

CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue - it mimics the signal that tells the pituitary to release growth hormone. Ipamorelin is a growth-hormone-releasing peptide (GHRP) - it works on a different receptor (the ghrelin receptor) and is often used alongside GHRH-type compounds in research. They are complementary, not interchangeable.^{[1], [2]}

How CJC-1295 works

CJC-1295 is a modified version of GHRH, the natural hormone that stimulates growth-hormone release. The modification was designed to make it last longer in the body. Studies in healthy adults report that a single administration can raise growth hormone and IGF-1 levels for days, which is why it is called a long-acting GHRH analogue.^{[3], [4]}

How Ipamorelin works

Ipamorelin belongs to a different family - the GHRPs. These compounds bind the ghrelin receptor and are studied for their ability to stimulate growth-hormone release through that pathway. Animal studies describe it as potent and long-acting for a GHRP, with a relatively selective profile.^[2]

Key differences at a glance

• Family: CJC-1295 is a GHRH analogue; Ipamorelin is a GHRP.
• Receptor: CJC-1295 targets GHRH signalling; Ipamorelin targets the ghrelin receptor.
• Duration: CJC-1295 has a long-acting profile in published human studies; Ipamorelin's profile is shorter.
• Human data: CJC-1295 has published healthy-adult studies; Ipamorelin's human evidence is thinner.
• Typical research use: they are often studied together as complementary GH-axis tools.

Why they are often paired

In research protocols, GHRH analogues and GHRPs are frequently combined because they act on different parts of the growth-hormone axis. That pairing is a design choice in research, not a recommendation - and any such protocol should be reviewed by the institutional ethics and safety processes that govern the experiment.^{[1], [2]}

What we still don't know

• How the two compounds compare head-to-head in controlled, modern studies
• Long-term effects of either compound - published data are short-term
• Optimal experimental conditions for the pair in animal models

Compliance reminder

Both compounds are supplied for research and educational purposes only. Neither is listed on the Australian Register of Therapeutic Goods (ARTG), and neither must be consumed by humans or animals.

Researching the GH axis? View CJC-1295 No DAC and Ipamorelin. For related research, see the CJC-1295 + Ipamorelin stack overview and Ipamorelin GHRH selectivity.